In conclusion, we have shown that pharmacological inhibition of PAI-1 prevents hepatic steatosis and reduces serum cholesterol levels through a mechanism that involves reduced PCSK9 synthesis (Fig. 6). This evidence concerns the gene SERPINE1 and fatty liver disease.